GSK 4069327A
Alternative Names: Flexyn2a; GSK-4069327A; GVXN-SD133; S4V2; Shigella 4V; Shigella dysenteriae bioconjugate vaccine - GlycoVaxyn; Shigella flexneri 2a vaccine - GlycoVaxyn; Shigella vaccine - LimmaTech Biologics; Shigella-4V2Latest Information Update: 21 Apr 2025
At a glance
- Originator GlycoVaxyn
- Developer GlycoVaxyn; Johns Hopkins Bloomberg School of Public Health; LimmaTech Biologics
- Class Bacterial vaccines; Conjugate vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Shigella infections
Most Recent Events
- 09 Apr 2025 LimmaTech Biologics plans a phase III trial for Shigella-infections
- 07 Apr 2025 LimmaTech Biologics initiates a phase-II trial in Shigella infections (In infants, Prevention) in Kenya (IM) (NCT06523231)
- 20 Mar 2025 LimmaTech plans phase II paediatric study in Low and middle income countries (LMIC) in the first half of 2025